SOUTH SAN FRANCISCO, Calif., April 10, 2017 (GLOBE NEWSWIRE) -- Five Prime Therapeutics, Inc. (Nasdaq:FPRX) today announced that it has completed enrollment in the initially planned 30-patient cohort ...
GDC-0449 in patients with advanced chondrosarcomas: A French Sarcoma Group (FSG)/French and U.S. National Cancer Institutes phase II collaborative study. This is an ASCO Meeting Abstract from the 2012 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback